Cover Image
市場調查報告書

主要已開發國家的全身性乾癬治療藥市場:生技藥品的持續性獲取和開發平台的新藥促進成長

Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth

出版商 GBI Research 商品編碼 295791
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
主要已開發國家的全身性乾癬治療藥市場:生技藥品的持續性獲取和開發平台的新藥促進成長 Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth
出版日期: 2014年02月07日 內容資訊: 英文
簡介

全身性乾癬治療藥市場,在8大市場整體,從2013年的50億美元,擴大到2020年的104億美元規模。這個成長由治療人口的增加與生物製品的獲取所帶動。

本報告提供主要已開發國家的全身性乾癬治療藥市場相關調查分析、市場概要、上市產品、開發平台分析、市場預測、最近的交易相關資訊等,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 概要
  • 流行病學
  • 病因、共生病症、危險因素
  • 病理學
  • 診斷
  • 治療的選項
  • 摘要

第3章 上市產品

  • 概要
  • Methotrexate(MTX)製劑
  • Sandimmune/Neoral(cyclosporine/modified cyclosporine)
  • Soriatane(acitretin)
  • Fumaderm(dimethyl fumarate,ethyl fumarate)
  • Humira(adalimumab)
  • Enbrel(etanercept)
  • Remicade(infliximab)
  • Stelara(ustekinumab)
  • 上市產品的熱圖

第4章 開發平台

  • 概要
  • 各階段、分子類型、計劃類型
  • 各目標分子
  • 臨床試驗狀況
  • 臨床試驗的失敗率
  • 一次/二次評估項目
  • 乾癬的臨床試驗摘要
  • 開發平台的有潛力分子
    • Ixekizumab
    • Xeljanz (tofacitinib)
    • Brodalumab
    • Apremilast
    • Secukinumab
  • 開發中產品的熱圖

第5章 市場預測

  • 概要
  • 全球市場
  • 北美
  • 歐洲主要5個國家
  • 日本
  • 推動市場要素與阻礙

第6章 共同開發與許可證交易

  • 共同開發交易
  • 許可證交易

第7章 附錄

圖表

目錄
Product Code: GBIHC322MR

GBI Research has released its pharma report "Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth". The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics.

Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period. Although the market will suffer revenue losses as a result of sales erosion from biosimilar competitors, this will be offset by the emergence of novel therapies. Most notably, these include monoclonal antibodies secukinumab, ixekizumab and brodalumab, which are currently being developed by Alcon (Novartis subsidiary), Eli Lilly and Amgen, respectively.

Scope

  • An introduction to psoriasis, which includes symptoms, epidemiology, etiology, pathophysiology, diagnosis and treatment
  • Analysis of the major systemic therapies in the current psoriasis marketed landscape
  • Analysis of the pipeline for psoriasis, which includes a breakdown of pipeline molecules by phase of development, molecule type, molecular target and novelty. Psoriasis clinical trials are analyzed by size, duration and failure rates, and a comparative analysis of the most promising systemic pipeline molecules is also provided.
  • Forecast projections for the systemic psoriasis market to 2020. Analysis is provided for the global market and each of the eight major markets. The forecast incorporates projected, low and high variance scenarios based on treatment usage patterns and annual therapy costs in each of the major markets.
  • Analysis of strategic consolidations, including co-development and licensing deals, within the psoriasis indication

Reasons to buy

  • Understand the current systemic psoriasis marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved
  • Identify trends and developments within the psoriasis pipeline and consider how the future competitive environment will be impacted
  • Consider market opportunities and potential risks by examining the psoriasis clinical trial landscape in relation to industry averages
  • Observe projections for treatment usage patterns, annual therapy costs and market growth in the eight major markets and understand reasons for variance in projected patterns of growth in the eight major markets

Abstract

The systemic psoriasis treatment market value in the eight major countries (8MM) - the US, Canada, France, Germany, Italy, Spain, the UK and Japan - is expected to more than double in the near future, jumping from $5 billion in 2013 to $10.4 billion by 2020, at a significant Compound Annual Growth Rate (CAGR) of 11.1%, forecasts business intelligence provider GBI Research.

The company's new report* states that across the 8MM, 4.1 million people were diagnosed with some form of moderate-to-severe psoriasis in 2013. This number is expected to climb slightly to 4.4 million by 2020, with 1.5 million of the population being treated with systemic agents.

Fiona Chisholm, Analyst for GBI Research, says: "This growth in the treatment population will be driven by a marginal rise in the global prevalence of psoriasis, as well as an increase in the diagnosis rate resulting from higher disease awareness and improved diagnostic methods.

"Additionally, psoriasis is increasingly being recognized as a serious systemic disease with associated quality of life impairment and disability, rather than as a simply cutaneous disease. As perceptions of psoriasis continue to change, healthcare professionals will consider treatment as non-optional."

Although some revenue losses are anticipated to occur throughout the forecast period, due to patent expiries, the introduction of new, novel biologics with positive efficacy profiles will drive further market growth.

According to GBI Research, secukinumab, brodalumab and ixekizumab are three particularly promising, late-stage pipeline monoclonal antibodies directly targeting IL-17, a pro-inflammatory cytokine. In addition to these upcoming biologics, some orally administered, small molecule compounds are also expected to enter the market over the coming years, such as Xeljanz, a janus kinase inhibitor, and apremilast, a PDE4 inhibitor.

"These pipeline molecules have demonstrated very strong efficacy and safety profiles, which are largely superior to those of the currently marketed products," Chisholm concludes.

*Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth

This report provides an analysis of the pipeline for psoriasis, including a breakdown of pipeline molecules by phase of development, molecule type, molecular target and novelty. Psoriasis clinical trials are analyzed by size, duration and failure rates, and a comparative analysis of the most promising systemic pipeline molecules is also provided.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Overview
  • 2.2. Epidemiology
  • 2.3. Etiology, Co-morbidities and Risk Factors
    • 2.3.1. Genetics
    • 2.3.2. Psoriatic Arthritis
    • 2.3.3. Mental Health Disorders
    • 2.3.4. Metabolic Syndrome, Smoking, Diet and Alcohol Consumption
    • 2.3.5. Infections
    • 2.3.6. Koebner Phenomenon
    • 2.3.7. Other Immune-mediated Diseases
  • 2.4. Pathophysiology
  • 2.5. Diagnosis
  • 2.6. Treatment Options
    • 2.6.1. Pharmacological Therapies
    • 2.6.2. Non-pharmacological Therapies
    • 2.6.3. Combination and Rotational Therapies
    • 2.6.4. Quality of Life Assessments
  • 2.7. Summary

3. Marketed Products

  • 3.1. Overview
  • 3.2. Methotrexate-based Products
  • 3.3. Sandimmune/Neoral (cyclosporine/modified cyclosporine) - Novartis
  • 3.4. Soriatane (acitretin) - Steifel Laboratories
  • 3.5. Fumaderm (dimethyl fumarate and ethyl fumarate) - Biogen Idec
  • 3.6. Humira (adalimumab) - Abbvie Inc.
  • 3.7. Enbrel (etanercept) - Amgen Inc.
  • 3.8. Remicade (infliximab) - Janssen Biotech
  • 3.9. Stelara (ustekinumab) - Janssen Biotech
  • 3.10. Marketed Products Heat Map

4. Pipeline

  • 4.1. Overview
  • 4.2. Pipeline Size and Distribution by Phase, Molecule Type and Program Type
  • 4.3. Pipeline Distribution by Molecular Target
  • 4.4. Clinical Trial Landscape
    • 4.4.1. Clinical Trial Duration
    • 4.4.2. Clinical Trial Size
  • 4.5. Clinical trial failure rates
  • 4.6. Primary and Secondary Endpoints
  • 4.7. Summary of Psoriasis Clinical Trials
  • 4.8. Promising pipeline molecules
    • 4.8.1. Ixekizumab - Eli Lilly
    • 4.8.2. Xeljanz (tofacitinib) - Pfizer
    • 4.8.3. Brodalumab - Amgen
    • 4.8.4. Apremilast - Celgene
    • 4.8.5. Secukinumab - Alcon
  • 4.9. Heat Map for Pipeline Products

5. Market Forecast to 2020

  • 5.1. Overview
  • 5.2. Global Market
  • 5.3. North America
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Treatment
    • 5.3.3. Market Size
  • 5.4. Top Five EU Markets
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Treatment
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Treatment
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers for the Systemic Psoriasis Therapeutics Market
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Co-development and Licensing deals

  • 6.1. Co-development Deals
    • 6.1.1. Abbvie Enters into Co-development Agreement with Biotest for Tregalizumab
    • 6.1.2. Lycera Enters into Research Agreement with Merck & Co.
    • 6.1.3. LEO Pharma Enters into Research Agreement with 4SC Discovery for Inflammatory Skin Diseases
    • 6.1.4. Amgen Enters into Co-Development Agreement with AstraZeneca for Five Human Monoclonal Antibodies Including Brodalumab
  • 6.2. Licensing Deals
    • 6.2.1. Leo Pharma Enters into Licensing Agreement with Virobay for Psoriasis Drug
    • 6.2.2. Foamix Enters into Licensing Agreement with Dr. Reddy's Labs
    • 6.2.3. Cipher Pharma Enters into Licensing Agreement with IBSA Institut Biochimique for Betesil Patch
    • 6.2.4. Phenex Pharma Enters into Licensing Agreement with Janssen Biotech for Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program

7. Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. Phase I
    • 7.1.4. Phase II
    • 7.1.5. Phase III
    • 7.1.6. Undisclosed
  • 7.2. Market Forecasts to 2020
    • 7.2.1. Major Developed Markets
    • 7.2.2. US
    • 7.2.3. UK
    • 7.2.4. France
    • 7.2.5. Germany
    • 7.2.6. Italy
    • 7.2.7. Spain
    • 7.2.8. Japan
    • 7.2.9. Canada
  • 7.3. Abbreviations
  • 7.4. References
  • 7.5. References for Heat Maps
    • 7.5.1. Marketed Products
    • 7.5.2. Pipeline products
  • 7.6. Methodology
    • 7.6.1. Secondary Research
    • 7.6.2. Therapeutic Landscape
  • 7.7. Contact Us
  • 7.8. Disclaimer

List of Tables

  • Table 1: Type of Psoriasis
  • Table 2: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Discovery, 2014
  • Table 3: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Preclinical/IND/CTA-filed, 2014
  • Table 4: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Phase I, 2014
  • Table 5: Systemic Psoriasis Therapeutics Market, Global, Phase II, Discovery, 2014
  • Table 6: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Phase III/Pre-registration, 2014
  • Table 7: Systemic Psoriasis Therapeutics Market, Global, Pipeline, Undisclosed, 2014
  • Table 8: Systemic Psoriasis Market Forecast, Global, 2013-2020
  • Table 9: Systemic Psoriasis Market Forecast, US, 2013-2020
  • Table 10: Systemic Psoriasis Market Forecast, UK, 2013-2020
  • Table 11: Systemic Psoriasis Market Forecast, France, 2013-2020
  • Table 12: Systemic Psoriasis Market Forecast, Germany, 2013-2020
  • Table 13: Systemic Psoriasis Market Forecast, Italy, 2013-2020
  • Table 14: Systemic Psoriasis Market Forecast, Spain, 2013-2020
  • Table 15: Systemic Psoriasis Market Forecast, Japan, 2013-2020
  • Table 16: Systemic Psoriasis Market Forecast, Canada, 2013-2020
  • Table 17: Breakdown of 'Others' Category
  • Table 18: Breakdown of 'Combination' Category

List of Figures

  • Figure 1: Psoriasis Treatment Algorithms
  • Figure 2: Heat Map for Marketed Products
  • Figure 3: Heat Map for Marketed Products (continued)
  • Figure 4: Psoriasis Therapeutics Market, Global, Pipeline, 2013
  • Figure 5: Psoriasis Therapeutics Market, Global, Pipeline by Molecular Target, 2013
  • Figure 6: Psoriasis Therapeutics Market, Global, Pipeline by Molecular Target, 2013
  • Figure 7: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Molecule Type, (months) 2006-2012
  • Figure 8: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Molecular Target, (months) 2006-2012
  • Figure 9: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Size by Molecule Type, (participants) 2006-2012
  • Figure 10: Psoriasis Therapeutics Market, Global, Pipeline, Clinical Trial Size by Molecular Target, (participants), 2006-2012
  • Figure 11: Psoriasis Therapeutics Market, Global, Clinical Trial Failure Rate, (%), 2006-2013
  • Figure 12: Psoriasis Therapeutics Market, Global, Frequency of Primary Endpoints Measured in Clinical Trials, (%), 2006-2012
  • Figure 13: Psoriasis Therapeutics Market, Global, Frequency of Secondary Endpoints Measured in Clinical Trials, (%), 2006-2012
  • Figure 14: Heat Map for Pipeline Products
  • Figure 15:Heat Map for Marketed Products
  • Figure 16:Heat Map for Marketed Products (continued)
  • Figure 17: Systemic Psoriasis Therapeutics Market, Global, Treatment Patterns (million), 2013-2020
  • Figure 18: Systemic Psoriasis Therapeutics Market, Global, Market Size ($bn), 2013-2020
  • Figure 19: Systemic Psoriasis Therapeutics Market, North America, Treatment Patterns, 2013-2020
  • Figure 20: Systemic Psoriasis Therapeutics Market, North America, Annual Cost of Treatment ($), 2013-2020
  • Figure 21: Systemic Psoriasis Therapeutics Market, North America, Market Size, 2013-2020
  • Figure 22: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Treatment Patterns ('000), 2013-2020
  • Figure 23: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2013-2020
  • Figure 24: Systemic Psoriasis Therapeutics Market, Top Five EU Countries, Market Size ($m), 2013-2020
  • Figure 25: Systemic Psoriasis Therapeutics Market, Japan, Treatment Patterns ('000), 2013-2020
  • Figure 26: Systemic Psoriasis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2013-2020
  • Figure 27: Systemic Psoriasis Therapeutics Market, Japan, Market Size ($m), 2013-2020
  • Figure 28: Psoriasis Therapeutics Market, Global, Co-development Deals, 2006-2013
  • Figure 29: Psoriasis Therapeutics Market, Global, Co-development Deals by Phase of Development, Molecule Type and Aggregate Deal Value ($m), 2006-2013
  • Figure 30: Psoriasis Therapeutics Market, Global, Licensing Deals, 2006-2013
  • Figure 31: Psoriasis Therapeutics Market, Licensing Deals by Phase, Molecule Type and Aggregate Deal Value ($m), 2006-2013
Back to Top